⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 2, 2025Open Access

Table S8 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Ismael A. Vergara Nigel G. Maher Alison J. Potter Elizabeth C. Paver Jordan W. Conway Serigne Lo Andrew J. Colebatch Georgina V. Long James S. Wilmott Richard A. Scolyer

View Full Paper

Ask AI

Bookmark

Share

Key Points

The bivariate genomic model predicts melanoma probability, indicating efficacy in diagnosis.
Key findings include a validation showing increased predictive accuracy of the model for melanoma risk.
This observational study employed a genomic model during discovery and validation phases for malignancy assessment.
Results highlight the potential for improved diagnostic strategies in identifying malignancy in melanocytic tumors.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

This analysis validates a genomic model predicting melanoma in primary melanocytic tumors, suggesting important diagnostic potential.

Abstract

Predicted probability of melanoma of the bivariate genomic model in discovery and validation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vergara et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f5f3 https://doi.org/10.1158/1078-0432.30029150

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S13 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
2Table S9 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
3Table S6 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
4Table S16 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
5Table S15 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
6Table S5 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
7Figure S4 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025
8Table S3 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors2025